Table 1.
Pilot/Phase 1 trials evaluating safety and clinical activity of in vivo activation of Vγ9Vδ2 T cells
| Year | Disease | Treatment | n | OR | CR | Reference |
|---|---|---|---|---|---|---|
| 2003 | MM NHL |
Pamidronate + IL-2 | 19 | 3/19 | 0/19 | [94] |
| 2003 | Prostate cancer Breast cancer |
Zoledronate | 9 | 0/9 | 0/9 | [95] |
| 2007 | Prostate cancer | Zoledronate vs zoledronate + IL-2 | 18 | 3/18 | 0/18 | [96] |
| 2010 | Breast cancer | Zoledronate + IL-2 | 10 | 0/10 | 0/10 | [97] |
| 2010 | RCC Colon cancer Esophagus cancer Gastric cancer Ovarian cancer Breast cancer |
BrHPP + IL-2 | 28 | 0/28 | 0/28 | [98] |
| 2011 | RCC | Zoledronate + IL-2 | 12 | 0/12 | 0/12 | [99] |
| 2012 | RCC MM AML |
Zoledronate + IL-2 | 21 | 2/21 | 0/21 | [100] |
| 2016 | Neuroblastoma | Zoledronate + IL-2 | 4 | 0/4 | 0/4 | [101] |
MM, multiple myeloma; NHL, non-Hodgkin lymphoma; RCC, renal cell cancer; AML, acute myeloid leukemia.